We are very excited to share the final results of the MEMMAT trial for the medullobastoma cohort- a gamme changer ! The results have been published by the JAMA Oncology journal. The article is entitled : Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen A Nonrandomized Controlled Trial MGHI is very proud to be part of this work. Andreas Peyrl; Monika Chocholous ; Magnus Sabel ; Alvaro Lassaletta ; Jaroslav Sterba; Pierre Leblond; Karsten (...)